Sherlock Biosciences develops CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™ platforms for rapid and accurate DNA and RNA detection. Their technology provides accessible diagnostic tests at the point-of-need, enabling timely health decisions and improving global health equity.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional diagnostic tests often require specialized laboratory equipment and trained personnel, limiting accessibility in resource-constrained settings and delaying time-to-results. This can hinder timely intervention and effective disease management, particularly in point-of-care scenarios and remote locations.
Solution
Sherlock Biosciences is developing diagnostic platforms leveraging CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™ technologies for rapid and accurate DNA and RNA detection. These platforms aim to decentralize testing by enabling accessible and affordable diagnostic tests at the point-of-need. By providing actionable information wherever and whenever it is needed, Sherlock Biosciences seeks to empower individuals to make informed health decisions and improve global health equity. The company's approach combines engineering biology with molecular diagnostics to create simple-to-use formats suitable for virtually any setting.
Target Audience
The primary target audience includes healthcare providers, researchers, and individuals in resource-limited settings who require rapid, accurate, and accessible diagnostic testing solutions.
Features
- CRISPR-based SHERLOCK™ platform for DNA detection
- Synthetic biology-based INSPECTR™ platform for RNA detection
- Rapid results enabling timely health decisions
- Accessible testing formats suitable for point-of-care settings
- Affordable diagnostic tests for widespread use